Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""MYELOPROLIFERATIVE disorders"" wg kryterium: Temat


Tytuł:
Platelets from patients with myeloproliferative neoplasms have increased numbers of mitochondria that are hypersensitive to depolarization by thrombin.
Autorzy:
Ross DM; Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, Australia. .; Department of Haematology, Royal Adelaide Hospital, 6E359, Port Rd, Adelaide, SA, 5000, Australia. .; Department of Haematology, Flinders University and Medical Centre, Adelaide, Australia. .; Adelaide Medical School, University of Adelaide, Adelaide, Australia. .
Liang HPH; ANZAC Research Institute, Concord Repatriation General Hospital, Sydney, NSW, Australia.
Iqra Z; Clinical and Health Sciences, University of South Australia, Adelaide, Australia.
Whittaker S; ANZAC Research Institute, Concord Repatriation General Hospital, Sydney, NSW, Australia.
Tan CW; ANZAC Research Institute, Concord Repatriation General Hospital, Sydney, NSW, Australia.
Dale BJ; Clinical and Health Sciences, University of South Australia, Adelaide, Australia.
Chen VM; ANZAC Research Institute, Concord Repatriation General Hospital, Sydney, NSW, Australia.; Department of Haematology, Concord Repatriation General Hospital, Sydney, NSW, Australia.; Faculty of Medicine and Health, Concord Clinical School, University of Sydney, Sydney, NSW, Australia.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Jun 06; Vol. 13 (1), pp. 9172. Date of Electronic Publication: 2023 Jun 06.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Myeloproliferative Disorders*/metabolism
Thrombocythemia, Essential*/metabolism
Thrombosis*/metabolism
Neoplasms*/metabolism
Humans ; Blood Platelets/metabolism ; Thrombin/metabolism ; Platelet Activation ; Mitochondria
Czasopismo naukowe
Tytuł:
Intratumoral heterogeneity of c-KIT mutations in a feline splenic mast cell tumor and their functional effects on cell proliferation.
Autorzy:
Hasegawa Y; Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan.
Shosu K; Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan.
Tsuji K; Laboratory of Veterinary Internal Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan.
Shimoyama Y; IDEXX Laboratories, Tokyo, Japan.
Miyama TS; Laboratory of Veterinary Internal Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan.
Baba K; Laboratory of Veterinary Internal Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan.
Okuda M; Laboratory of Veterinary Internal Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan.
Itamoto K; Laboratory of Small Animal Clinical Science, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan.
Igase M; Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan.
Mizuno T; Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Sep 22; Vol. 12 (1), pp. 15791. Date of Electronic Publication: 2022 Sep 22.
Typ publikacji:
Journal Article
MeSH Terms:
Myeloproliferative Disorders*/genetics
Myeloproliferative Disorders*/veterinary
Spleen*/pathology
Amino Acids/genetics ; Animals ; Cat Diseases/genetics ; Cats ; Cell Proliferation/genetics ; DNA, Complementary ; Interleukin-3/genetics ; Mast Cells/metabolism ; Mice ; Mutation ; Nucleotides ; Proto-Oncogene Proteins c-kit/metabolism ; Receptor Protein-Tyrosine Kinases/genetics
Czasopismo naukowe
Tytuł:
Mutations in the miR-142 gene are not common in myeloproliferative neoplasms.
Autorzy:
Galka-Marciniak P; Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.
Kanduła Z; Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.
Tire A; Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.
Wegorek W; Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.
Gwozdz-Bak K; Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.
Handschuh L; Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.; Institute of Computing Science, Poznan University of Technology, Poznan, Poland.
Giefing M; Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland.
Lewandowski K; Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.
Kozlowski P; Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Jun 28; Vol. 12 (1), pp. 10924. Date of Electronic Publication: 2022 Jun 28.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Leukemia, Lymphocytic, Chronic, B-Cell*
Leukemia, Myeloid, Acute*
MicroRNAs*/genetics
Myeloproliferative Disorders*/genetics
Myeloproliferative Disorders*/pathology
Humans ; Mutation
Czasopismo naukowe
Tytuł:
Incidence of myeloid neoplasms in Spain (2002-2013): a population-based study of the Spanish network of cancer registries.
Autorzy:
Solans M; Research Group on Statistics, Econometrics and Health (GRECS), University of Girona, Girona, Spain. .; CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. .
Sanvisens A; Epidemiology Unit and Girona Cancer Registry, Josep Carreras Leukaemia Research Institute, Girona, Spain.
Ameijide A; Tarragona Cancer Registry, Cancer Prevention and Epidemiology Service, Sant Joan de Reus University Hospital, Tarragona, Spain.
Merino S; Department of Health, Asturias Cancer Registry, Public Health Directorate, Asturias, Spain.
Rojas D; Canary Islands Cancer Registry, Public Health Directorate, Canary Islands Government, Las Palmas, Spain.
Alemán A; Canary Islands Cancer Registry, Public Health Directorate, Canary Islands Government, Las Palmas, Spain.
Banqueri E; Castellón Cancer Registry, Public Health Directorate, Valencian Government, Castellón, Spain.
Chico M; Ciudad Real Cancer Registry, Health and Social Welfare Authority, Castile-La Mancha, Spain.
Marcos AI; Cuenca Cancer Registry, Health and Social Welfare Authority, Castile-La Mancha, Spain.
de Castro V; Basque Country Cancer Registry, Basque Government, Vitoria-Gasteiz, Spain.
Gil L; Basque Country Cancer Registry, Basque Government, Vitoria-Gasteiz, Spain.
de Munain AL; Basque Country Cancer Registry, Basque Government, Vitoria-Gasteiz, Spain.
Puigdemont M; Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Catalan Institute of Oncology, Girona Biomedical Research Institute Dr. Josep Trueta (IDIBGI), Girona, Spain.
Sánchez MJ; CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Granada Cancer Registry, Andalusian School of Public Health (EASP), Instituto de Investigación Biosanitaria Ibs.GRANADA, University of Granada, Granada, Spain.
Perucha J; La Rioja Cancer Registry, Epidemiology and Health Prevention Service, Logroño, Spain.
Ruiz-Armengol P; Mallorca Cancer Registry, Public Health and Participation Department, Palma de Mallorca, Spain.
Chirlaque MD; CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Department of Epidemiology, Regional Health Authority, IMIB-Arrixaca, Murcia University, Murcia, Spain.
Guevara M; CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Navarra Cancer Registry, Navarra Public Health Institute, Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
Carulla M; Tarragona Cancer Registry, Cancer Prevention and Epidemiology Service, Sant Joan de Reus University Hospital, Tarragona, Spain.
Marcos-Gragera R; CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain.; Epidemiology Unit and Girona Cancer Registry, Josep Carreras Leukaemia Research Institute, Girona, Spain.; Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Catalan Institute of Oncology, Girona Biomedical Research Institute Dr. Josep Trueta (IDIBGI), Girona, Spain.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Jan 10; Vol. 12 (1), pp. 323. Date of Electronic Publication: 2022 Jan 10.
Typ publikacji:
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Leukemia, Myeloid, Acute/*epidemiology
Myelodysplastic Syndromes/*epidemiology
Myeloproliferative Disorders/*epidemiology
Adult ; Aged ; Aged, 80 and over ; Female ; Health Surveys ; Humans ; Incidence ; Leukemia, Myeloid, Acute/diagnosis ; Male ; Middle Aged ; Myelodysplastic Syndromes/diagnosis ; Myeloproliferative Disorders/diagnosis ; Registries ; Spain/epidemiology ; Time Factors
Czasopismo naukowe
Tytuł:
Incidence, characteristics and risk factors of thromboembolic events in East Asian patients with BCR-ABL1 negative myeloproliferative neoplasms.
Autorzy:
Kim J; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Korea.
Byun JM; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Korea. .; Cancer Research Institute, Seoul National University College of Medicine, Seoul, 110744, Korea. .; Center for Medical Innovation, Biomedical Research Institute, Seoul National University Hospital, Seoul, 110744, Korea. .
Hong J; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, 110744, Korea.; Center for Medical Innovation, Biomedical Research Institute, Seoul National University Hospital, Seoul, 110744, Korea.
Koh Y; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, 110744, Korea.; Center for Medical Innovation, Biomedical Research Institute, Seoul National University Hospital, Seoul, 110744, Korea.
Shin DY; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, 110744, Korea.; Center for Medical Innovation, Biomedical Research Institute, Seoul National University Hospital, Seoul, 110744, Korea.
Kim I; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Korea.
Yoon SS; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, 110744, Korea.; Center for Medical Innovation, Biomedical Research Institute, Seoul National University Hospital, Seoul, 110744, Korea.
Park H; Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, 07061, Korea.
Bang SM; Department of Internal Medicine, Seoul Nationl University College of Medicine, Seoul National University Bundang Hospital, Seongnam, 463-707, Korea.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2021 Sep 08; Vol. 11 (1), pp. 17819. Date of Electronic Publication: 2021 Sep 08.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Fusion Proteins, bcr-abl/*genetics
Myeloproliferative Disorders/*complications
Thromboembolism/*epidemiology
Adult ; Aged ; Aged, 80 and over ; Asia, Eastern/epidemiology ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Myeloproliferative Disorders/genetics ; Retrospective Studies ; Risk Factors ; Survival Rate ; Thromboembolism/etiology ; Thromboembolism/genetics ; Young Adult
Czasopismo naukowe
Tytuł:
CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.
Autorzy:
Belcic Mikic T; Department of Haematology, University Medical Centre Ljubljana, Zaloska 7, 1000, Ljubljana, Slovenia. .; Faculty of Medicine, University of Ljubljana, Korytkova 2, 1000, Ljubljana, Slovenia. .
Pajic T; Department of Haematology, University Medical Centre Ljubljana, Zaloska 7, 1000, Ljubljana, Slovenia.; Faculty of Medicine, University of Maribor, Taborska ulica 8, 2000, Maribor, Slovenia.
Sever M; Department of Haematology, University Medical Centre Ljubljana, Zaloska 7, 1000, Ljubljana, Slovenia.; Faculty of Medicine, University of Ljubljana, Korytkova 2, 1000, Ljubljana, Slovenia.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2019 Dec 27; Vol. 9 (1), pp. 19838. Date of Electronic Publication: 2019 Dec 27.
Typ publikacji:
Journal Article
MeSH Terms:
Mutation*
Calreticulin/*genetics
Janus Kinase 2/*genetics
Myeloproliferative Disorders/*genetics
Thrombocythemia, Essential/*genetics
Adult ; Calreticulin/classification ; Calreticulin/metabolism ; Cohort Studies ; DNA Mutational Analysis/methods ; Female ; Genetic Testing/methods ; Hematologic Neoplasms/diagnosis ; Hematologic Neoplasms/genetics ; Hematologic Neoplasms/metabolism ; Humans ; Janus Kinase 2/metabolism ; Male ; Middle Aged ; Myeloproliferative Disorders/diagnosis ; Myeloproliferative Disorders/metabolism ; Reproducibility of Results ; Sensitivity and Specificity ; Thrombocythemia, Essential/diagnosis ; Thrombocythemia, Essential/metabolism
Czasopismo naukowe
Tytuł:
Reversine exhibits antineoplastic activity in JAK2 -positive myeloproliferative neoplasms.
Autorzy:
Lima K; Department of Pharmacology, Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil.
Carlos JAEG; Department of Pharmacology, Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil.
Alves-Paiva RM; Einstein's Teaching and Research Institute, Albert Einstein Hospital, São Paulo, Brazil.
Vicari HP; Department of Pharmacology, Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil.
Souza Santos FP; Einstein's Teaching and Research Institute, Albert Einstein Hospital, São Paulo, Brazil.
Hamerschlak N; Einstein's Teaching and Research Institute, Albert Einstein Hospital, São Paulo, Brazil.
Costa-Lotufo LV; Department of Pharmacology, Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil.
Traina F; Department of Medical Images, Hematology and Clinical Oncology, University of São Paulo at Ribeirão Preto Medical School, Ribeirão Preto, São Paulo, Brazil.
Machado-Neto JA; Department of Pharmacology, Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2019 Jul 09; Vol. 9 (1), pp. 9895. Date of Electronic Publication: 2019 Jul 09.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Apoptosis*
Mutation*
Biomarkers, Tumor/*metabolism
Gene Expression Regulation, Neoplastic/*drug effects
Janus Kinase 2/*metabolism
Morpholines/*pharmacology
Myeloproliferative Disorders/*pathology
Purines/*pharmacology
Aurora Kinase A/genetics ; Aurora Kinase A/metabolism ; Aurora Kinase B/genetics ; Aurora Kinase B/metabolism ; Biomarkers, Tumor/genetics ; Cell Cycle ; Cell Proliferation ; Humans ; Janus Kinase 2/genetics ; Myeloproliferative Disorders/genetics ; Myeloproliferative Disorders/metabolism ; Protein Kinase Inhibitors ; Tumor Cells, Cultured
Czasopismo naukowe
Tytuł:
Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms.
Autorzy:
Sapre M; Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Tremblay D; Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Wilck E; Department of Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
James A; Division of Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Leiter A; Division of Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Coltoff A; Department of Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Koshy AG; Department of Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Kremyanskaya M; Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.; Tisch Cancer Institute at Mount Sinai, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Hoffman R; Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.; Tisch Cancer Institute at Mount Sinai, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Mascarenhas JO; Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.; Tisch Cancer Institute at Mount Sinai, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.
Gallagher EJ; Division of Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA. .; Tisch Cancer Institute at Mount Sinai, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2019 Nov 12; Vol. 9 (1), pp. 16609. Date of Electronic Publication: 2019 Nov 12.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Bone Marrow Neoplasms/*drug therapy
Janus Kinase 1/*antagonists & inhibitors
Janus Kinase 2/*antagonists & inhibitors
Myeloproliferative Disorders/*drug therapy
Pyrazoles/*therapeutic use
Adipose Tissue/drug effects ; Adipose Tissue/enzymology ; Adipose Tissue/metabolism ; Adult ; Aged ; Aged, 80 and over ; Animals ; Blotting, Western ; Body Mass Index ; Body Weight/drug effects ; Bone Marrow Neoplasms/metabolism ; Disease Models, Animal ; Humans ; Male ; Mice ; Mice, Inbred C57BL ; Middle Aged ; Myeloproliferative Disorders/metabolism ; Nitriles ; Pyrimidines ; Retrospective Studies
Czasopismo naukowe
Tytuł:
High expression of EZH2 as a marker for the differential diagnosis of malignant and benign myogenic tumors.
Autorzy:
Zhang N; School of Basic Medicine, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, People's Republic of China.
Zeng Z; Department of Pathology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei Provicne, People's Republic of China.
Li S; Pathology Center, Shanghai General Hospital/Faculty of Basic Medicine, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200025, People's Republic of China.
Wang F; Second Department of Neurosurgery, The First Affiliated Hospital of Kunming Medical University, Kunming, 650032, Yunnan Province, People's Republic of China.
Huang P; School of Clinical Medicine, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, People's Republic of China. huangp_.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2018 Aug 17; Vol. 8 (1), pp. 12331. Date of Electronic Publication: 2018 Aug 17.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Gene Expression*
Enhancer of Zeste Homolog 2 Protein/*genetics
Myeloproliferative Disorders/*diagnosis
Myeloproliferative Disorders/*genetics
Adult ; Aged ; Aged, 80 and over ; Biomarkers ; Diagnosis, Differential ; Enhancer of Zeste Homolog 2 Protein/metabolism ; Female ; Humans ; Immunohistochemistry ; Male ; Middle Aged ; Myeloproliferative Disorders/metabolism ; RNA, Messenger/genetics ; RNA, Messenger/metabolism ; Reproducibility of Results ; Sensitivity and Specificity
Czasopismo naukowe
Tytuł:
Distinct effects of V617F and exon12-mutated JAK2 expressions on erythropoiesis in a human induced pluripotent stem cell (iPSC)-based model.
Autorzy:
Nilsri N; Doctor of Philosophy Program in Medical Sciences, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.; Department of Medical Technology, Faculty of Allied Health Sciences, Naresuan University, Phitsanulok, Thailand.
Jangprasert P; Interdisciplinary Program of Biomedical Sciences, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Pawinwongchai J; Faculty of Medical Technology, Rangsit University, Pathum Thani, Thailand.
Israsena N; Stem Cell and Cell Therapy Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Rojnuckarin P; Research Unit in Translational Hematology, Division of Hematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, 10330, Thailand. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2021 Mar 04; Vol. 11 (1), pp. 5255. Date of Electronic Publication: 2021 Mar 04.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Janus Kinase 2/*genetics
Polycythemia/*genetics
Polycythemia Vera/*genetics
STAT1 Transcription Factor/*genetics
STAT3 Transcription Factor/*genetics
Erythropoiesis/genetics ; Exons ; Gene Expression Regulation/genetics ; Humans ; Induced Pluripotent Stem Cells/metabolism ; Mutation/genetics ; Myeloproliferative Disorders/genetics ; Myeloproliferative Disorders/pathology ; Polycythemia/pathology ; Polycythemia Vera/pathology ; Primary Myelofibrosis ; STAT Transcription Factors/genetics ; Thrombocythemia, Essential/genetics ; Thrombocythemia, Essential/pathology ; Thrombocytosis/genetics ; Thrombocytosis/pathology
Czasopismo naukowe
Tytuł:
Neutrophil extracellular trap formation and circulating nucleosomes in patients with chronic myeloproliferative neoplasms.
Autorzy:
Marin Oyarzún CP; Department of Hematology Research, Institute of Medical Research 'Alfredo Lanari', University of Buenos Aires, National Council for Scientific and Technological Research (CONICET), Buenos Aires, Argentina.
Carestia A; Laboratory of Experimental Thrombosis, Institute of Experimental Medicine (IMEX)- CONICET, National Academy of Medicine, Buenos Aires, Argentina.
Lev PR; Department of Hematology Research, Institute of Medical Research 'Alfredo Lanari', University of Buenos Aires, National Council for Scientific and Technological Research (CONICET), Buenos Aires, Argentina.
Glembotsky AC; Department of Hematology Research, Institute of Medical Research 'Alfredo Lanari', University of Buenos Aires, National Council for Scientific and Technological Research (CONICET), Buenos Aires, Argentina.
Castro Ríos MA; Consultorios Hematológicos, Buenos Aires, Argentina.
Moiraghi B; Department of Hematology, Hospital Ramos Mejía, Buenos Aires, Argentina.
Molinas FC; Department of Hematology Research, Institute of Medical Research 'Alfredo Lanari', University of Buenos Aires, National Council for Scientific and Technological Research (CONICET), Buenos Aires, Argentina.
Marta RF; Department of Hematology Research, Institute of Medical Research 'Alfredo Lanari', University of Buenos Aires, National Council for Scientific and Technological Research (CONICET), Buenos Aires, Argentina.
Schattner M; Laboratory of Experimental Thrombosis, Institute of Experimental Medicine (IMEX)- CONICET, National Academy of Medicine, Buenos Aires, Argentina.
Heller PG; Department of Hematology Research, Institute of Medical Research 'Alfredo Lanari', University of Buenos Aires, National Council for Scientific and Technological Research (CONICET), Buenos Aires, Argentina.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2016 Dec 13; Vol. 6, pp. 38738. Date of Electronic Publication: 2016 Dec 13.
Typ publikacji:
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Biomarkers, Tumor/*blood
Extracellular Traps/*metabolism
Hematologic Neoplasms/*blood
Myeloproliferative Disorders/*blood
Nucleosomes/*metabolism
Adult ; Aged ; Aged, 80 and over ; Chronic Disease ; Female ; Hematologic Neoplasms/pathology ; Humans ; Male ; Middle Aged ; Myeloproliferative Disorders/pathology ; Neutrophils/metabolism ; Neutrophils/pathology ; Peroxidase/blood ; Reactive Oxygen Species/blood
Czasopismo naukowe
Tytuł:
Comprehensive Gene expression meta-analysis and integrated bioinformatic approaches reveal shared signatures between thrombosis and myeloproliferative disorders.
Autorzy:
Jha PK; Defence Institute of Physiology and Allied Sciences, Delhi, INDIA.
Vijay A; Defence Institute of Physiology and Allied Sciences, Delhi, INDIA.
Sahu A; Defence Institute of Physiology and Allied Sciences, Delhi, INDIA.
Ashraf MZ; Defence Institute of Physiology and Allied Sciences, Delhi, INDIA.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2016 Nov 28; Vol. 6, pp. 37099. Date of Electronic Publication: 2016 Nov 28.
Typ publikacji:
Journal Article; Meta-Analysis
MeSH Terms:
Transcriptome*
Myeloproliferative Disorders/*genetics
Polycythemia Vera/*genetics
Thrombocythemia, Essential/*genetics
Biomarkers/metabolism ; Databases, Genetic ; Humans ; Microarray Analysis ; Myeloproliferative Disorders/complications ; Polycythemia Vera/complications ; Thrombocythemia, Essential/complications
Czasopismo naukowe
Tytuł:
Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells.
Autorzy:
Philips ST; Division of Hematology/Oncology, Department of Internal Medicine, Southwestern Medical Center, University of Texas, Dallas, TX, USA.
Hildenbrand ZL; Division of Hematology/Oncology, Department of Internal Medicine, Southwestern Medical Center, University of Texas, Dallas, TX, USA.
Oravecz-Wilson KI; University of Michigan, Ann Arbor, MI, USA.
Foley SB; Division of Hematology/Oncology, Department of Internal Medicine, Southwestern Medical Center, University of Texas, Dallas, TX, USA.
Mgbemena VE; Division of Hematology/Oncology, Department of Internal Medicine, Southwestern Medical Center, University of Texas, Dallas, TX, USA.
Ross TS; Division of Hematology/Oncology, Department of Internal Medicine, Southwestern Medical Center, University of Texas, Dallas, TX, USA.
Pokaż więcej
Źródło:
Oncogene [Oncogene] 2014 Nov 13; Vol. 33 (46), pp. 5379-90. Date of Electronic Publication: 2013 Nov 18.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Benzamides/*pharmacology
Myeloproliferative Disorders/*drug therapy
Neoplastic Stem Cells/*drug effects
Piperazines/*pharmacology
Pyrimidines/*pharmacology
Animals ; Antineoplastic Agents/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Arsenic Trioxide ; Arsenicals/administration & dosage ; Benzamides/administration & dosage ; Blotting, Western ; Bone Marrow Transplantation ; Core Binding Factor Alpha 2 Subunit/genetics ; Core Binding Factor Alpha 2 Subunit/metabolism ; DNA-Binding Proteins/genetics ; DNA-Binding Proteins/metabolism ; Disease Models, Animal ; Drug Resistance, Neoplasm/drug effects ; Drug Resistance, Neoplasm/genetics ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic/drug effects ; Granulocyte Colony-Stimulating Factor/administration & dosage ; Hematopoietic Stem Cells/drug effects ; Hematopoietic Stem Cells/metabolism ; Humans ; Imatinib Mesylate ; Mice, Inbred C57BL ; Mice, Transgenic ; Myeloproliferative Disorders/genetics ; Myeloproliferative Disorders/metabolism ; Neoplasm Recurrence, Local ; Neoplastic Stem Cells/metabolism ; Oligonucleotide Array Sequence Analysis ; Oxides/administration & dosage ; Piperazines/administration & dosage ; Pyrimidines/administration & dosage ; Reverse Transcriptase Polymerase Chain Reaction ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms.
Autorzy:
Arranz L; Stem Cell Niche Pathophysiology Group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain.
Sánchez-Aguilera A; Stem Cell Niche Pathophysiology Group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain.
Martín-Pérez D; Stem Cell Niche Pathophysiology Group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain.
Isern J; Stem Cell Niche Pathophysiology Group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain.
Langa X; Stem Cell Niche Pathophysiology Group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain.
Tzankov A; University Hospital Basel, CH-4031 Basel, Switzerland.
Lundberg P; University Hospital Basel, CH-4031 Basel, Switzerland.
Muntión S; Department of Haematology, IBSAL-Hospital Universitario de Salamanca, 37007 Salamanca, Spain.
Tzeng YS; National Taiwan University, Taipei 10002, Taiwan.
Lai DM; National Taiwan University, Taipei 10002, Taiwan.
Schwaller J; University Hospital Basel, CH-4031 Basel, Switzerland.
Skoda RC; University Hospital Basel, CH-4031 Basel, Switzerland.
Méndez-Ferrer S; Stem Cell Niche Pathophysiology Group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain.
Pokaż więcej
Źródło:
Nature [Nature] 2014 Aug 07; Vol. 512 (7512), pp. 78-81. Date of Electronic Publication: 2014 Jun 22.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Stem Cell Niche*
Hematopoietic Stem Cells/*pathology
Myeloproliferative Disorders/*pathology
Neoplasms/*pathology
Nerve Fibers/*pathology
Sympathetic Nervous System/*pathology
Adrenergic beta-3 Receptor Agonists/pharmacology ; Adrenergic beta-3 Receptor Agonists/therapeutic use ; Animals ; Apoptosis/drug effects ; Disease Progression ; Female ; Hematopoietic Stem Cells/drug effects ; Humans ; Interleukin-1beta/metabolism ; Janus Kinase 2/genetics ; Mesenchymal Stem Cells/drug effects ; Mesenchymal Stem Cells/pathology ; Mice ; Myeloproliferative Disorders/drug therapy ; Neoplasms/drug therapy ; Neoplastic Stem Cells/drug effects ; Neoplastic Stem Cells/pathology ; Nerve Fibers/drug effects ; Nestin/metabolism ; Neuroprotective Agents/pharmacology ; Neuroprotective Agents/therapeutic use ; Receptors, Adrenergic, beta-3/metabolism ; Schwann Cells/drug effects ; Schwann Cells/pathology ; Sympathetic Nervous System/drug effects ; Sympathetic Nervous System/physiopathology
Czasopismo naukowe
Tytuł:
Role of the adaptor protein LNK in normal and malignant hematopoiesis.
Autorzy:
Gery S; Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA. />Koeffler HP
Pokaż więcej
Źródło:
Oncogene [Oncogene] 2013 Jun 27; Vol. 32 (26), pp. 3111-8. Date of Electronic Publication: 2012 Oct 08.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
MeSH Terms:
Hematopoiesis*
Hematologic Neoplasms/*metabolism
Myeloproliferative Disorders/*metabolism
Proteins/*metabolism
Adaptor Proteins, Signal Transducing ; Animals ; Autoimmune Diseases/metabolism ; Cardiovascular Diseases/metabolism ; Cell Differentiation ; Hematologic Neoplasms/genetics ; Humans ; Intracellular Signaling Peptides and Proteins ; Mice ; Myeloproliferative Disorders/genetics ; Protein Interaction Maps ; Protein-Tyrosine Kinases/genetics ; Protein-Tyrosine Kinases/metabolism ; Signal Transduction
Czasopismo naukowe
Tytuł:
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.
Autorzy:
Koppikar P; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Bhagwat N
Kilpivaara O
Manshouri T
Adli M
Hricik T
Liu F
Saunders LM
Mullally A
Abdel-Wahab O
Leung L
Weinstein A
Marubayashi S
Goel A
Gönen M
Estrov Z
Ebert BL
Chiosis G
Nimer SD
Bernstein BE
Verstovsek S
Levine RL
Pokaż więcej
Źródło:
Nature [Nature] 2012 Sep 06; Vol. 489 (7414), pp. 155-9.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Protein Multimerization*
Signal Transduction*/drug effects
Janus Kinase 2/*antagonists & inhibitors
Janus Kinase 2/*metabolism
Myeloproliferative Disorders/*drug therapy
STAT Transcription Factors/*metabolism
Animals ; Cell Line ; Disease Models, Animal ; Drug Resistance, Neoplasm/drug effects ; Enzyme Activation/drug effects ; Gene Knockdown Techniques ; Granulocytes/drug effects ; Granulocytes/enzymology ; Granulocytes/metabolism ; HSP90 Heat-Shock Proteins/antagonists & inhibitors ; HSP90 Heat-Shock Proteins/metabolism ; Humans ; Janus Kinase 1/biosynthesis ; Janus Kinase 1/deficiency ; Janus Kinase 1/genetics ; Janus Kinase 1/metabolism ; Janus Kinase 2/deficiency ; Janus Kinase 2/genetics ; Mice ; Myeloproliferative Disorders/enzymology ; Myeloproliferative Disorders/metabolism ; Myeloproliferative Disorders/pathology ; Phosphorylation ; Protein Biosynthesis ; RNA Interference ; TYK2 Kinase/biosynthesis ; TYK2 Kinase/deficiency ; TYK2 Kinase/genetics ; TYK2 Kinase/metabolism
Czasopismo naukowe
Tytuł:
Clinical evidence for a graft-versus-tumour effect following allogeneic HSCT for t(8;13) atypical myeloproliferative disorder.
Autorzy:
Townsend W
Cross NC
Waghorn K
Somana K
Ramsay A
Thomson K
Peggs K
Pokaż więcej
Źródło:
Bone marrow transplantation [Bone Marrow Transplant] 2009 Aug; Vol. 44 (3), pp. 197-9. Date of Electronic Publication: 2009 Feb 23.
Typ publikacji:
Case Reports; Letter
MeSH Terms:
Graft vs Tumor Effect*
Hematopoietic Stem Cell Transplantation*
Myeloproliferative Disorders/*therapy
Adult ; Chromosomes, Human, Pair 13 ; Chromosomes, Human, Pair 8 ; Humans ; Male ; Myeloproliferative Disorders/genetics ; Myeloproliferative Disorders/immunology ; Myeloproliferative Disorders/pathology
Raport
Tytuł:
The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro.
Autorzy:
von Bubnoff N; III. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, München, Germany. />Gorantla SP
Engh RA
Oliveira TM
Thöne S
Aberg E
Peschel C
Duyster J
Pokaż więcej
Źródło:
Oncogene [Oncogene] 2011 Feb 24; Vol. 30 (8), pp. 933-43. Date of Electronic Publication: 2010 Oct 25.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents/*pharmacology
Drug Resistance, Neoplasm/*genetics
Myeloproliferative Disorders/*genetics
Protein Kinase Inhibitors/*pharmacology
Receptor, Platelet-Derived Growth Factor alpha/*chemistry
Receptor, Platelet-Derived Growth Factor alpha/*genetics
Amino Acid Sequence ; Benzamides ; Benzenesulfonates/pharmacology ; Blotting, Western ; Cell Line, Tumor ; Humans ; Imatinib Mesylate ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics ; Molecular Sequence Data ; Mutagenesis, Site-Directed ; Mutation ; Myeloproliferative Disorders/drug therapy ; Niacinamide/analogs & derivatives ; Phenylurea Compounds ; Piperazines/pharmacology ; Protein Structure, Tertiary ; Pyridines/pharmacology ; Pyrimidines/pharmacology ; Reverse Transcriptase Polymerase Chain Reaction ; Sorafenib ; Structure-Activity Relationship
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies